Navigation Links
GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
Date:12/1/2011

FARMINGTON, Conn., Dec. 1, 2011 /PRNewswire-iReach/ -- Global Information, Inc. presents "Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"  by GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20111201/CG15993)

Polycystic ovarian syndrome (PCOS) is a common chronic disorder of the endocrine system in women. It mostly affects women of reproductive age (12-45 years old) and is thought to be one of the main causes of female subfertility. It is characterized by a heterogeneous appearance of anovulation, hyperandrogenemia, or secondary metabolic problems such as obesity, insulin resistance and so on.

Other names for this syndrome are polycystic ovary disease (PCOD), functional ovarian hyperandrogenism, Stein-Leventhal syndrome, ovarian hyperthecosis and sclerocystic ovary syndrome

Static growth in the PCOS Therapeutics Market in the Forecast Period

The global PCOS market was valued at $656m in 2010; GlobalData estimates the PCOS market to reach $804m by 2018 growing at a CAGR of 2.6% in the forecast period.

The rising prevalent population of co-morbid conditions such as diabetes, obesity and dyslipidemia are the key driver for the static growth in PCOS therapeutics market. The market does not have an approved drug. Treatment options include generic and off-label drugs which have lower efficacy profiles, which mean that both physician and patient satisfaction are low.

The etiology and pathology of PCOS is not clearly understood. Therefore it is difficult to identify the cause of the disease and develop a drug against it, which means that the current therapies rely on treating the symptoms rather than the disease.

The majority of participants in the PCOS therapeutics pipeline are institutions or universities. Company participation is low because most of the drugs under trial are generics and already being used for this indication, either alone or in combination. Therefore, the current pipeline products are unlikely to impact the market significantly.

Increasing Disease Population to Contribute to Market Growth

Patient population of PCOS is increasing due to a rise in co-morbid conditions such as diabetes, obesity and other cardiovascular complications. 60 million people are obese, a figure which almost doubled in the last 14 years (CDC study, Sept. 2006).

On average, 5%-10% of women suffer from PCOS. During the last decade, various programs have been created to spread awareness of the syndrome. In 2005, the American Association of Clinical Endocrinologists launched an awareness campaign to spread information regarding its complications and treatments. After this, the number of cases of self reported symptoms increased considerably.

Lack of Approved Drugs and Disease Modifiying Therapies a Barrier to PCOS Market Growth

The current PCOS therapeutics market has no specific approved products to treat the syndrome. The current drugs which are used to treat the associated condition of PCOS are generic and off-label products. Therefore the presence of generics poses a threat for the growth of the market both now and in the future. The unavailablilty of approved drug and usage of generic and off-label drugs which have low costs of therapy further reduces the revenue generated by the market.

The market mainly relies upon treating associated conditions of PCOS by using various generic and off-label products, and there is no single product which can treat all the conditions of PCOS. Current therapies are less efficacious, so patient and physician satisfaction is low. There are few companies involved in the development of molecules which can satisfy the huge unmet need of the market. There is a lack of diasease-modifying therapies for the treatment of all the conditions associated with PCOS. Most of the drugs in the clinical trials have already been used to treat this syndrome in some way or other, and these drugs lack sufficient information on safety and efficacy. This demonstrates a weak pipeline which will not encourage growth in the forecast period and acts as a barrier to market growth.

Find pharmaceutical market research, industry forecasts, and business analysis: http://www.giiresearch.com/pharmaceutical_report.shtml

About Global Information Inc.

Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact:  Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
3. A New Target in Polycystic Kidney Disease
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
6. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
10. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
11. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):